Recent research findings have demonstrated the effectiveness of combining TVB-2640 with bevacizumab, an inhibitor of angiogenesis that inhibits the vascular endothelial growth factor (VEGF), which is a protein abundantly expressed by tumor cells. The gene discussed is VEGFA; the disease is neoplasm.